Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HiLo: high versus low dose radioiodine with or without rhTSH for remnant ablation in differentiated thyroid cancer
2005-003687-37Phase 3Unknown
- Sponsor
- University College London
- Start
- Jul 2006
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 3, randomised trial of iodine-131 and thyrotropin alfa in well-differentiated thyroid cancer (WDTC) (4 arms), sponsored by University College London. Primary endpoint: Successful remnant ablation at 6–8 months. Status: unknown.
02
Drugs
iodine-131thyrotropin alfa
03
Conditions
well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on 2005-003687-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003687-37.